Drugs / XPF-001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00813670 | Nov 2008 → May 2009 | — | Xenon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01090622 | Apr → Aug 2010 | primary erythermalgia | Xenon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00954356 | Sep → Nov 2009 | — | Xenon Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XPF-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01090622 ↗ |
| Route | Oral | “Single oral dose, or 6 days of repeated oral doses.” NCT00813670 ↗ |